Bausch Health Companies Inc. (TSE:BHC - Get Free Report)'s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as C$8.79 and last traded at C$8.83, with a volume of 328023 shares changing hands. The stock had previously closed at C$9.22.
Analysts Set New Price Targets
Separately, Royal Bank of Canada lifted their price objective on Bausch Health Companies from C$8.00 to C$9.00 and gave the company a "sector perform" rating in a research report on Friday, February 23rd.
Check Out Our Latest Research Report on Bausch Health Companies
Bausch Health Companies Stock Performance
The company has a quick ratio of 0.58, a current ratio of 1.23 and a debt-to-equity ratio of 7,583.76. The stock has a market cap of C$3.28 billion, a P/E ratio of -5.26, a price-to-earnings-growth ratio of 0.21 and a beta of 0.90. The firm's 50-day moving average is C$11.95 and its two-hundred day moving average is C$11.14.
Bausch Health Companies (TSE:BHC - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The company reported C$1.55 earnings per share for the quarter, beating the consensus estimate of C$1.36 by C$0.19. Bausch Health Companies had a negative return on equity of 686.52% and a negative net margin of 5.07%. The company had revenue of C$3.28 billion during the quarter, compared to analysts' expectations of C$3.05 billion. As a group, research analysts expect that Bausch Health Companies Inc. will post 4.8307692 EPS for the current year.
Bausch Health Companies Company Profile
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
